ARA-290 vs Teriparatide

Non-hematopoietic EPO analogue; activates innate repair receptor (IRR/EPOR/CD131 complex) without erythropoietic effects; promotes tissue repair and nerve healing

ARA 290 (cibinetide) is a synthetic 11-amino-acid peptide derived from the helix B region of erythropoietin (EPO), engineered to activate the innate repair receptor (IRR) — a tissue-protective heteroreceptor complex comprising the EPO receptor and the β-common receptor (CD131) — without engaging the classical erythropoietic EpoR homodimer, thereby separating EPO's tissue-protective signaling from its hematopoietic effects. By selectively engaging the IRR rather than the erythropoietic receptor, cibinetide activates anti-inflammatory and anti-apoptotic intracellular pathways in neurons, endothelium, and other metabolically active tissues without causing erythrocytosis, hypertension, or thrombosis, making it a candidate for neuropathy and inflammatory tissue injury contexts. Randomized, double-blind Phase 2 clinical trials have demonstrated that cibinetide improves metabolic control and neuropathic symptom scores in patients with type 2 diabetes, and a separate study demonstrated improved corneal nerve fiber abundance in patients with sarcoidosis-associated small fiber neuropathy — providing human proof-of-concept for both diabetic and inflammatory peripheral neuropathy applications. Cibinetide (ARA 290) is an investigational compound that has not received FDA approval for any indication; Phase 2 data supports further investigation in peripheral neuropathies, but no Phase 3 completion or regulatory filing has occurred as of 2025.

Recombinant PTH 1-34; when given intermittently, preferentially activates osteoblasts over osteoclasts; increases bone remodeling and net bone formation; stimulates IGF-1 in bone

Teriparatide (PTH(1-34); Forteo) is a synthetic 34-amino-acid peptide corresponding to the biologically active N-terminal fragment of endogenous parathyroid hormone, developed as the first FDA-approved anabolic bone agent for osteoporosis — a compound that stimulates new bone formation rather than merely inhibiting bone resorption. Teriparatide activates the PTH/PTHrP receptor (PTH1R) on osteoblasts; when administered as intermittent pulsatile subcutaneous injections, it drives net bone formation by stimulating osteoblast activity, increasing bone mineral density, improving trabecular microarchitecture, and reducing fracture risk — a distinct mechanism from antiresorptive agents such as bisphosphonates. A comprehensive systematic review and network meta-analysis published in the Annals of Internal Medicine (2023), integrating multiple randomized controlled trials, established teriparatide among the most effective pharmacological interventions for fracture prevention in osteoporosis, with significant reductions in vertebral and non-vertebral fracture risk versus placebo. Teriparatide (Forteo, Eli Lilly) is FDA-approved and requires a prescription; it is indicated for postmenopausal women, men with osteoporosis, and glucocorticoid-induced osteoporosis at high fracture risk, with a maximum treatment duration of two years due to preclinical osteosarcoma findings; biosimilar teriparatide preparations are available in multiple international markets.